Eli Lilly and

Eli Lilly and

Yahoo Finance • 14 hours ago

Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) shares rose about 2% on Wednesday after new prescription data indicated its oral weight-loss drug Wegovy continued to lead the U.S. market over Eli Lilly's Foundayo. The r... Full story

Yahoo Finance • 14 hours ago

Lilly's Obesity Pill Trails Wegovy

This article first appeared on GuruFocus. Eli Lilly (LLY, Financials), the pharmaceutical company behind several diabetes and weight-loss treatments, is off to a slower start than expected with its new obesity pill. Warning! GuruFocus ha... Full story

Yahoo Finance • 14 hours ago

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 19 hours ago

Three Biotechs Deliver Catalysts to Watch

DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ: NTHI), Ernexa Therapeutics(NASDAQ: ERNA), and VivoSim Labs(NASDAQ: VIVS) highlight three distinct pathways to potentia... Full story

Yahoo Finance • 20 hours ago

Jim Cramer crowns one surging sector the hottest in the market

For most of 2026, the market's story has mostly been on semiconductors and artificial intelligence. Jim Cramer just told investors to look somewhere else. On his CNBC show, the "Mad Money" host called biotechnology the hottest group in th... Full story

Yahoo Finance • 21 hours ago

Eli Lilly’s obesity pill is said to trail Novo’s even three months after launch

[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Novo Nordisk’s (NVO [https://seekingalpha.com/symbol/NVO]) Wegovy pill remains the overwhelming favorite in the market for oral weight loss drugs even three months afte... Full story

Yahoo Finance • 22 hours ago

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Labs, Inc. SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety... Full story

Yahoo Finance • 23 hours ago

3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech

With the Nasdaq-100 Index up 18.5% year to date, an advantage of more than 700 basis points over the S&P 500, it's safe to say, at least in broad terms, that tech stocks are performing well and that group remains top-of-mind for many inves... Full story

Yahoo Finance • yesterday

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report 2026 provides strategists, marketers, invest... Full story

Yahoo Finance • yesterday

Eli Lilly (LLY) Wins Full FDA Approval For Retevmo In Broader Cancers

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET... Full story

Yahoo Finance • 2 days ago

Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem

The presentation on Biogen’s experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects. Instead, Biogen stock is down 6%, to $197. Tuesday’s presentation on the drug dirane... Full story

Yahoo Finance • 2 days ago

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) today participate in one of the most exciting growth markets in healthcare: the weight loss drug market, one that's on track to reach nearly $100 billion in a few years. Novo was the first... Full story

Yahoo Finance • 3 days ago

Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group

This article first appeared on GuruFocus. Cathie Wood's ARK Invest increased positions in several technology, healthcare and digital asset companies during the week ended July 10, while reducing holdings in select semiconductor and genomi... Full story

Yahoo Finance • 3 days ago

Apex Fintech Solutions Releases Q2 2026 Investor Pulse Report: SpaceX IPO Draws Universal Demand as Retail Rotates Into the AI Buildout

New data shows the SpaceX (SPCX) listing became the quarter's single largest net buy across every generation, while retail rotated out of the spring's energy and commodity trades and into memory and AI infrastructure, and net sold Tesla N... Full story

Yahoo Finance • 3 days ago

Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku

Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52... Full story

Yahoo Finance • 3 days ago

Capital Square Fully Subscribes Richmond Active-Adult DST Offering

165-unit, Class A community in fast-growing Richmond suburb draws investor demand amid Eli Lilly and LEGO expansions in the region RICHMOND, Va., July 13, 2026--(BUSINESS WIRE)--Capital Square, a leading sponsor of tax-advantaged real est... Full story

Yahoo Finance • 3 days ago

Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors

Eli Lilly (NYSE: LLY) commands a market capitalization of about $1.06 trillion, and that valuation was built largely on two drugs: Mounjaro and Zepbound. Investors talk about the drugmaker's weight-loss and diabetes franchise constantly. B... Full story

Yahoo Finance • 5 days ago

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Key Points State Street Health Care Select Sector SPDR ETF offers a lower expense ratio and a higher dividend yield than Invesco Nasdaq Biotechnology ETF Invesco Nasdaq Biotechnology ETF provides concentrated exposure to the biotech indus... Full story

Yahoo Finance • 5 days ago

Which is the Better Choice for Healthcare Investors? IYH or BBH?

Investors choosing between iShares U.S. Healthcare ETF (NYSEMKT:IYH) and VanEck Biotech ETF (NASDAQ:BBH) may weigh the broader, lower-volatility healthcare exposure of IYH against the concentrated, high-growth biotechnology focus of BBH.... Full story